24/7 Market News Snapshot 13 June, 2025 – Vaxart, Inc Common Stock (NASDAQ:VXRT)
DENVER, Colo., 13 June, 2025 (www.247marketnews.com) – (Nasdaq:VXRT) are discussed in this article.
Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology firm recognized for its groundbreaking oral recombinant vaccines, has seen its stock soar by over 30% today, opening at $0.517 and currently trading at $0.700 on a substantial trading volume of 28.66 million shares. This remarkable surge signals increasing investor confidence in the company’s potential within the biotech sector, presenting attractive opportunities for both existing and prospective shareholders.
In conjunction with this market movement, Vaxart successfully convened its Annual Meeting of Stockholders through a virtual platform, where critical decisions shaping the future of the company were made. Preliminary voting outcomes revealed that shareholders overwhelmingly supported the election of six director nominees, ensuring their service until the 2026 Annual Meeting. Additionally, stockholders ratified WithumSmith+Brown, PC as the independent registered public accounting firm for Vaxart.
However, two significant proposals faced rejection from stockholders: an amendment to the Restated Certificate of Incorporation for a reverse stock split and the advisory “say-on-pay” vote concerning compensation for the company’s named executive officers. Vaxart is currently reviewing its options and strategies in response to this input from shareholders, emphasizing its commitment to aligned governance and operational transparency.
As a leader in developing oral vaccines, Vaxart aims to enhance patient accessibility and safety while tackling major health challenges, including COVID-19, norovirus, and seasonal influenza. The company is poised to advance its innovative approach, focusing on bringing effective oral vaccine solutions to market. Stakeholders are encouraged to monitor Vaxart’s progress as it continues to forge pathways in the biotechnology landscape.